Dynavax to Present at the 4th Annual Evercore Virtual ISI HealthCONx Conference

Rhea-AI Summary

Dynavax Technologies Corporation (NASDAQ: DVAX) announced that CEO Ryan Spencer will participate in a virtual fireside chat at the 4th Annual Evercore virtual ISI HealthCONx Conference on November 30 at 2:40 p.m. E.T. The live audio webcast can be accessed via the company's Investors section. A replay will be available for 30 days post-event. Dynavax is known for its HEPLISAV-B® vaccine approved for hepatitis B prevention and is advancing its CpG 1018 adjuvant for various vaccines.

EMERYVILLE, Calif., Nov. 18, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the 4th Annual Evercore virtual ISI HealthCONx Conference on Tuesday, November 30, at 2:40 p. m. E.T.

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, plague, Tdap, and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:
Nicole Arndt, Investor Relations and Corporate Communications
narndt@dynavax.com 
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-the-4th-annual-evercore-virtual-isi-healthconx-conference-301428589.html

SOURCE Dynavax Technologies

FAQ

When is Ryan Spencer participating in the Evercore ISI HealthCONx Conference for Dynavax (DVAX)?

Ryan Spencer will participate in the conference on November 30 at 2:40 p.m. E.T.

How can I access the live webcast for Dynavax's conference presentation?

The live audio webcast can be accessed through the 'Investors' section on Dynavax's website.

What is the main product marketed by Dynavax (DVAX)?

Dynavax's main product is HEPLISAV-B®, a vaccine for the prevention of hepatitis B.

What is the focus of Dynavax's research collaborations?

Dynavax is focused on developing adjuvanted vaccines for COVID-19, plague, Tdap, and universal influenza.

How long will the replay of the webcast for Dynavax's conference be available?

The replay of the webcast will be available for 30 days following the live event.